Biogen
BIIB
955 hedge funds and large institutions have $28B invested in Biogen in 2024 Q1 according to their latest regulatory filings, with 104 funds opening new positions, 306 increasing their positions, 355 reducing their positions, and 144 closing their positions.
0.41% more ownership
Funds ownership: 88.84% → 89.26% (+0.41%)
0% more call options, than puts
Call options by funds: $303M | Put options by funds: $303M
5% less funds holding
Funds holding: 1,003 → 955 (-48)
14% less repeat investments, than reductions
Existing positions increased: 306 | Existing positions reduced: 355
16% less capital invested
Capital invested by funds: $33.3B → $28B (-$5.33B)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
28% less first-time investments, than exits
New positions opened: 104 | Existing positions closed: 144
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$507M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$140M |
| 3 |
BGC
Beutel, Goodman & Co
Toronto,
Ontario, Canada
|
+$134M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$93.7M |
| 5 |
VanEck Associates
New York
|
+$74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$151M |
| 2 |
CG
Carmignac Gestion
Paris,
France
|
-$93.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$89.1M |
| 4 |
JP Morgan Chase
New York
|
-$82.6M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$82.1M |
BIIB Hedge Fund Activity: Q1 2024 in Review
955 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2024, worth a combined $28B — down 16% from $33.3B a quarter earlier.
Sellers outnumbered buyers: 144 funds closed out of BIIB and 104 opened new positions — a net loss of 40 holders — while 355 trimmed existing stakes and 306 added.
The largest buyer was Vanguard Group, adding an estimated $507M. The largest seller was First Trust Advisors, cutting an estimated $151M.
- 955 institutional investors held Biogen (BIIB) as of Q1 2024, down from 1,003 in Q4 2023.
- Funds reported $28B of Biogen stock for Q1 2024, down 16% quarter-over-quarter.
- 104 funds opened new Biogen positions in Q1 2024 and 144 closed out, a net change of -40 holders.
- The largest Biogen buyer in Q1 2024 was Vanguard Group, an estimated $507M added.
- The largest Biogen seller in Q1 2024 was First Trust Advisors, an estimated $151M sold.
Based on aggregated 13F filings for Q1 2024.